Pediatric Hodgkin Lymphoma; Experience with Euronet Pediatric Hodgkin Lymphoma Protocol in a Developing Country

Annals of hematology & oncology Pub Date : 2018-10-01 DOI:10.26420/ANNHEMATOLONCOL.2018.1214

Tariq Ghafoor

{"title":"Pediatric Hodgkin Lymphoma; Experience with Euronet Pediatric Hodgkin Lymphoma Protocol in a Developing Country","authors":"Tariq Ghafoor","doi":"10.26420/ANNHEMATOLONCOL.2018.1214","DOIUrl":null,"url":null,"abstract":"Objective: To analyse outcome of Paediatric Hodgkin Lymphoma (HL) patients treated with Euronet Paediatric Hodgkin Lymphoma treatment protocol in a developing country. Patients and Methods: This is a prospective study conducted at Paediatric Oncology department at Combined Military Hospital (CMH) Rawalpindi, Pakistan. All newly diagnosed cases of HL, less than 18years registered from January 2012 onwards that completed their treatment until 30th June 2018 were included. Data regarding age, sex, staging, histopathology and outcome were analysed. Results: Total 102 patients including 80 (78.4%) males and 22 (21.6%) females were analysed. The mean age was 7.54±2.77 years. B symptoms were present in 58 (56.9%) patients. Ten (9.8%) patients had stage I disease, 33 (32.4%) stage II, 41 (40.2%) stage III and 18 (17.6%) stage IV disease. Mixed cellularity was the commonest histological subtype seen in 74 (72.5%) patients. Involved field radiotherapy was given to 17 (16.7%) patients having inadequate response after 2 cycles of OEPA chemotherapy. Eight (7.8%) patients died of treatment related complications and 10 (9.8%) patients relapsed. Nine of the relapsed (90%) cases responded to 2 nd line treatment including one requiring autologous stem cell transplant. One relapsed patient died of progressive disease. Overall Survival (OS) and Event Free Survival (EFS) was 91.2% and 82.4% respectively. Conclusion: In Pakistan, mixed cellularity is the commonest HL subtype seen in young males. Long duration of disease before presentation, malnutrition, presence of symptoms, disease is","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hematology & oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26420/ANNHEMATOLONCOL.2018.1214","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Objective: To analyse outcome of Paediatric Hodgkin Lymphoma (HL) patients treated with Euronet Paediatric Hodgkin Lymphoma treatment protocol in a developing country. Patients and Methods: This is a prospective study conducted at Paediatric Oncology department at Combined Military Hospital (CMH) Rawalpindi, Pakistan. All newly diagnosed cases of HL, less than 18years registered from January 2012 onwards that completed their treatment until 30th June 2018 were included. Data regarding age, sex, staging, histopathology and outcome were analysed. Results: Total 102 patients including 80 (78.4%) males and 22 (21.6%) females were analysed. The mean age was 7.54±2.77 years. B symptoms were present in 58 (56.9%) patients. Ten (9.8%) patients had stage I disease, 33 (32.4%) stage II, 41 (40.2%) stage III and 18 (17.6%) stage IV disease. Mixed cellularity was the commonest histological subtype seen in 74 (72.5%) patients. Involved field radiotherapy was given to 17 (16.7%) patients having inadequate response after 2 cycles of OEPA chemotherapy. Eight (7.8%) patients died of treatment related complications and 10 (9.8%) patients relapsed. Nine of the relapsed (90%) cases responded to 2 nd line treatment including one requiring autologous stem cell transplant. One relapsed patient died of progressive disease. Overall Survival (OS) and Event Free Survival (EFS) was 91.2% and 82.4% respectively. Conclusion: In Pakistan, mixed cellularity is the commonest HL subtype seen in young males. Long duration of disease before presentation, malnutrition, presence of symptoms, disease is

查看原文本刊更多论文

儿童霍奇金淋巴瘤;发展中国家Euronet儿童霍奇金淋巴瘤方案的经验

目的：分析发展中国家儿童霍奇金淋巴瘤（HL）患者接受Euronet儿童霍奇金淋巴瘤治疗方案的疗效。患者和方法：这是一项在巴基斯坦拉瓦尔品第联合军事医院（CMH）儿科肿瘤科进行的前瞻性研究。从2012年1月起登记的所有新诊断的HL病例，不到18岁，并且在2018年6月30日之前完成了治疗，都包括在内。对有关年龄、性别、分期、组织病理学和结果的数据进行了分析。结果：共分析102例患者，其中男性80例（78.4%），女性22例（21.6%）。平均年龄7.54±2.77岁。58例（56.9%）患者出现B症状。10名（9.8%）患者患有I期疾病，33名（32.4%）患者患有II期疾病，41名（40.2%）患者患有III期疾病，18名（17.6%）患者患IV期疾病。混合细胞是74例（72.5%）患者中最常见的组织学亚型。17名（16.7%）患者在2个周期的OEPA化疗后反应不足，接受了介入野放疗。8名（7.8%）患者死于治疗相关并发症，10名（9.8%）患者复发。9例复发病例（90%）对二线治疗有反应，其中1例需要自体干细胞移植。一名复发患者死于进行性疾病。总生存率（OS）和无事件生存率（EFS）分别为91.2%和82.4%。结论：在巴基斯坦，混合细胞是年轻男性中最常见的HL亚型。发病前疾病持续时间长，营养不良，出现症状，疾病

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of hematology & oncology

自引率

0.00%

发文量